EANS-Adhoc: - Marseille-Kliniken AG appoints two Management Board members - New Management Board function strengthens IT development

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

03.03.2010

Berlin, 3 March 2010. Marseille-Kliniken AG (Prime Standard, ISIN DE
0007783003, MKA) has appointed Claus Dobrowolski (53) and Axel
Regenhardt (46) to the Management Board. Claus Dobrowolski is to head
Finance from 2 April 2010, while Axel Regenhardt is to assume
responsibility for a new function on the Management Board with
immediate effect, managing IT, Operations and Auditing at the listed
health services provider. Axel Hölzer, in charge of operating
business at Marseille-Kliniken AG since 2002, will remain CEO.

Claus Dobrowolski holds a degree in business administration and is
currently in an executive position at Sasol Germany as Director -
Special Assignments. The company is part of the South African Sasol
Group, employs around 1,500 employees in Germany and produces
surfactants and their primary products, inorganic speciality
chemicals and olefins. Dobrowolski was a member of the Executive
Board at Sasol Wax International AG, the global leader in the field
of paraffin wax and paraffin related products, for seven years until
March 2009 and as CFO (Chief Financial Officer) was also responsible
for strategy in addition to finance.

IT specialist Axel Regenhardt has held a number of executive
positions within the group of companies in Marseille-Kliniken AG. In
his previous position, he was the Group´s general agent and the
director of Business Service Management at VDSE GmbH (an
administration service provider for social institutions). The company
develops and implements custom IT solutions for care, rehabilitation
and acute care institutions operated by the health service provider.

By installing the new function on the Management Board,
Marseille-Kliniken AG is strengthening its business activities in the
IT sector. The last few years have seen the Group make substantial
investments into software development. At the moment, the Company
owns more than 20 software solutions, which are deployed to structure
processes in companies providing services in the field of healthcare.
The focus of IT applications is on safeguarding and reviewing quality
inside care institutions. The Group is planning to enhance its
activities in this segment.

End of ad hoc release

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Marseille-Kliniken AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Hillermann Consulting

Christian Hillermann

Investor Relations for Marseille-Kliniken AG

Poststraße 14/16

20354 Hamburg

Germany

Tel.: +49-(0)40 / 320 279-10

Fax: +49-(0)40 / 320 279-114

www.hillermann-consulting.de

Marseille-Kliniken AG

Dr. Ute Buchheim

Friedrich-Ebert-Str. 65

33330 Gütersloh

Germany

Tel.: +49-(0)5241/90 39-35

Fax: +49-(0)5241/90 39-39

www.marseille-kliniken.com

Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hamburg / regulated dealing